Home » Newsletters » BioWorld

BioWorld

March 19, 2008

View Archived Issues

Possible Vasculitis Case Halts Heplisav Trials, Dynavax Falls

The news sent shares of Dynavax (NASDAQ:DVAX) plunging 58.6 percent, closing Tuesday at $2.16, down $3.06. (BioWorld Today) Read More

Nuvelo Halting Alfimeprase After Phase II Study Failure

Approval Letter on Ceftobiprole Sends Basilea Shares Plunging

Alimera Closes $30M Financing, Boosts Stake in Medidur FA

BioNumerik's Tavocept Shows Trend Only in 'Small' Phase III

Prometic, Sartorius Pact Taps into Asian Markets

Other News To Note

Clinic Roundup

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Flow Neuro wins FDA nod for at-home device for depression
BioWorld MedTech
Flow Neuroscience AB received U.S. FDA 510(k) approval for its Flow at-home brain-stimulation device to treat major depressive disorder. The wearable headset uses...